Organon & CO Form 4 insider transactions

Ferreira Juan Camilo Arjona, Head of R&D & CMO of Organon & Co., reported multiple transactions in common stock on August 11, 2026.

Shalini Sharp, a Director at Organon & Co., reported transactions involving phantom stock units, reflecting her participation in the company's Non-Employee Director Savings Plan.

Ramona Sequeira, a Director at Organon & Co., reported a transaction involving phantom stock units, reflecting an economic equivalent of common stock.

Cynthia M. Patton, a Director at Organon & Co., acquired 17,857.143 phantom stock units on June 12, 2026, as part of the company's Non-Employee Director Savings Plan.

Philip Ozuah, a Director at Organon & Co., reported a transaction involving phantom stock units.

Deborah R. Leone, a Director at Organon & Co., reported a transaction involving phantom stock units, reflecting an economic equivalent to common stock.

Rochelle B. Lazarus, a Director at Organon & Co., reported transactions involving phantom stock units, reflecting her beneficial ownership and participation in the company's savings plan.

Helene D. Gayle, a Director at Organon & Co., reported the acquisition of 17,857.143 phantom stock units on June 12, 2026, under the company's Non-Employee Director Savings Plan.

Alan Ezekowitz, a Director at Organon & Co., reported the acquisition of phantom stock units, reflecting a strategic compensation component for non-employee directors.

Robert Essner, a Director at Organon & Co., reported the acquisition of 17,857.143 phantom stock units on June 12, 2026, as part of the company's Non-Employee Director Savings Plan.

Lynette Holzbaur, SVP and Corporate Controller at Organon & Co., reported transactions involving the acquisition and subsequent sale of company common stock.

Lynette Holzbaur, SVP and Corporate Controller at Organon & Co., reported a transaction involving the acquisition of common stock.

Juliana Drinane, Interim Head of Mfg & Supply at Organon & Co., reported the vesting of restricted stock units and a new equity grant.

Head of R&D and CMO Juan Camilo Arjona Ferreira reported the vesting of restricted stock units and a new equity grant.

Executive VP Daniel Karp acquired shares through RSU vesting and disposed of shares to cover tax obligations.

Chief Information Officer Rachel Stahler exercised restricted stock units and withheld shares for tax obligations.

Organon & Co. CFO Matthew Walsh reported the vesting of restricted stock units and the grant of new equity awards in a recent SEC Form 4 filing.

Organon & Co. Chief Human Resources Officer Aaron Falcione reported the vesting of restricted stock units and a new grant of 166,944 units.

General Counsel Kirke Weaver reported the vesting of restricted stock units and the withholding of shares for tax obligations.

Vittorio Nisita, Head of Global Business Services at Organon & Co., reported the vesting of restricted stock units and a new equity grant in a Form 4 filing.

SVP and Corporate Controller Lynette Holzbaur reported the vesting of restricted stock units and the receipt of new equity grants at Organon & Co.

Interim CEO Joseph T. Morrissey Jr. reported the vesting of restricted stock units and a new grant of 333,889 units in Organon & Co.

Organon & Co.'s Executive VP, Corporate Development, Daniel Karp, reported the vesting and conversion of Restricted Stock Units into common stock, alongside a related tax withholding transaction.

Organon & Co.'s General Counsel, Kirke Weaver, reported the vesting of Restricted Stock Units and subsequent share transactions.

Organon's Head of Global Business Services, Vittorio Nisita, exercised restricted stock units and sold a portion of the resulting common stock to cover tax obligations.

Organon & Co. Interim Head of Manufacturing & Supply, Juliana Drinane, reported the vesting of 7,979 Restricted Stock Units and the subsequent sale of 2,733 shares for tax withholding.

Organon & Co.'s Head of R&D and CMO, Juan Camilo Arjona Ferreira, reported the exercise of Restricted Stock Units and subsequent sale of shares for tax withholding purposes.

Organon & Co.'s Chief Financial Officer, Matthew M. Walsh, increased his direct beneficial ownership of common stock by 9,909 shares after RSU vesting and tax-related sales.

Organon & Co.'s Chief Human Resources Officer, Aaron Falcione, reported planned future acquisitions and dispositions of common stock related to performance share units and dividend equivalents under a Rule 10b5-1 plan.

Organon & Co.'s Chief Financial Officer, Matthew M. Walsh, reported the acquisition and disposition of common stock related to performance share unit vesting and tax withholdings.